A Pilot Trial of HU14.18-IL2 (EMD273063) in Subjects With Completely Resectable Recurrent Stage III or Stage IV Melanoma

Trial Profile

A Pilot Trial of HU14.18-IL2 (EMD273063) in Subjects With Completely Resectable Recurrent Stage III or Stage IV Melanoma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Jun 2015

At a glance

  • Drugs Monoclonal antibody ch14 18 interleukin-2 fusion protein (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Jun 2015 Planned End Date changed from 1 Dec 2011 to 1 Jan 2020 as per ClinicalTrials.gov record.
    • 03 Jun 2015 Status changed from completed to active, no longer recruiting as per ClinicalTrials.gov record.
    • 03 Jun 2014 Results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top